CGRP Receptor Antagonist Compounds for Migraine Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for migraine and other CGRP-related disorders are limited, and there is a need for more effective CGRP receptor antagonists to manage these conditions.
Innovation Solution
Development of novel compounds with specific structural features that act as CGRP receptor antagonists, including various ring systems and linker groups, to treat a wide range of disorders involving CGRP receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing CGRP receptor antagonists are used, then migraine treatment is provided, but treatment effectiveness is limited and more effective antagonists are needed
Solution Approach 1:
The patent applies parameter changes by systematically varying structural parameters of the CGRP receptor antagonist molecules, including different ring systems (pyrrolidine, piperidine, morpholine), various linker groups, and diverse substituent patterns. These structural parameter modifications enable the development of compounds with improved binding affinity and selectivity for the CGRP receptor, thereby enhancing treatment effectiveness while maintaining broad applicability across different migraine types and CGRP-related disorders
Solution Approach 2:
The patent employs composite material principles by creating complex molecular structures that combine multiple functional elements: heterocyclic ring systems, linker moieties, and various substituents are integrated into unified antagonist molecules. These composite structures leverage the synergistic effects of different structural components to achieve optimal receptor binding characteristics, improved pharmacokinetic properties, and enhanced therapeutic efficacy compared to simpler analogs
2Measurement precision
If novel compounds with specific structural features are developed, then CGRP receptor targeting is improved, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the CGRP receptor antagonist into distinct structural modules: a heterocyclic ring system (pyrrolidine, piperidine, or morpholine), a linker group connecting the ring to the aromatic substituent, and various functional substituents. This modular segmentation allows for systematic optimization of each component's contribution to receptor binding precision while managing overall molecular complexity through rational design and selective combination of elements
Solution Approach 2:
The patent implements local quality by introducing specific functional groups and substituents at particular positions on the molecular structure to enhance local interactions with the CGRP receptor binding site. Different substituents (halogens, alkyl groups, aryl groups) are strategically placed to create optimal local chemical environments for receptor engagement, thereby improving targeting precision without requiring uniform complexity throughout the entire molecule
Data Source
AI summary
The disclosures herein relate to novel compounds of Formula (1): and salts thereof, wherein A1, A2, Q, X, R1, R2 and R3 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with CGRP receptors.